0001179110-21-010820.txt : 20211210
0001179110-21-010820.hdr.sgml : 20211210
20211210160318
ACCESSION NUMBER: 0001179110-21-010820
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211208
FILED AS OF DATE: 20211210
DATE AS OF CHANGE: 20211210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cavanaugh Sarah
CENTRAL INDEX KEY: 0001709113
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-15006
FILM NUMBER: 211485254
MAIL ADDRESS:
STREET 1: C/O CELLDEX THERAPEUTICS, INC.
STREET 2: 53 FRONTAGE ROAD, SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Celldex Therapeutics, Inc.
CENTRAL INDEX KEY: 0000744218
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 133191702
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
BUSINESS PHONE: 908-200-7500
MAIL ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
FORMER COMPANY:
FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC
DATE OF NAME CHANGE: 19980828
FORMER COMPANY:
FORMER CONFORMED NAME: T CELL SCIENCES INC
DATE OF NAME CHANGE: 19920703
4
1
edgar.xml
FORM 4 -
X0306
4
2021-12-08
0
0000744218
Celldex Therapeutics, Inc.
CLDX
0001709113
Cavanaugh Sarah
C/O CELLDEX THERAPEUTICS, INC.
53 FRONTAGE ROAD, SUITE 220
HAMPTON
NJ
08827
0
1
0
0
SVP of Corp Affairs & Admin.
Common Stock
2021-12-08
4
M
0
1857
9.0165
A
2265
D
Common Stock
2021-12-08
4
M
0
5466
10.38
A
7731
D
Common Stock
2021-12-08
4
S
0
7323
40.00
D
408
D
Incentive Stock Option (Right to Buy)
9.0165
2021-12-08
4
M
0
1857
0.00
D
2028-06-13
Common Stock
1857
11458
D
Incentive Stock Option (Right to Buy)
10.38
2021-12-08
4
M
0
5466
0.00
D
2030-06-18
Common Stock
5466
78534
D
The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 10, 2021.
25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
/s/ Sam Martin, attorney-in-fact for Sarah Cavanaugh
2021-12-10